2,5-dioxopyrrolidin-1-yl 3-nitrobenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,5-dioxopyrrolidin-1-yl 3-nitrobenzoate
• 英文别名: (2,5-Dioxopyrrolidin-1-yl) 3-nitrobenzoate
• 化学式: C₁₁H₈N₂O₆
• 分子量: 264.194
• InChiKey: PFOOCKDHBKZXAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  110
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,5-dioxopyrrolidin-1-yl 3-nitrobenzoate 、 1-氨基癸烷 生成 3-nitro-N-decylbenzamide
  参考文献：
  名称：

  YAMASHINA, TAKAO;HIGUCHI, KATSUHIKO;HIRATA, HIROFUMI, YUKAGAKU, 37,(1988) N, S. 349-355

  摘要：

  DOI：
• 作为产物：
  描述：

  1-碘-3-硝基苯 、 2,5-dioxopyrrolidin-1-yl formate 在 palladium diacetate 、 三乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 2-甲基四氢呋喃 为溶剂， 反应 10.0h， 以78%的产率得到2,5-dioxopyrrolidin-1-yl 3-nitrobenzoate
  参考文献：
  名称：

  Palladium-Catalyzed Carbonylation of (Hetero)Aryl, Alkenyl and Allyl Halides by Means of N-Hydroxysuccinimidyl Formate as CO Surrogate

  摘要：

  An efficient Pd-catalyzed carbonylation protocol is described for the coupling of a large panel of aryl, heteroaryl, benzyl, vinyl and allyl halides 2 with the unusual N-hydroxysuccinimidyl (NHS) formate 1 as a CO surrogate to afford the corresponding valuable NHS esters 3. High conversion to the coupling products was achieved with up to 98% yield by means of Pd(OAc)(2)/Xantphos catalyst system.

  DOI：

  10.1021/acs.joc.5b01119

文献信息

• Metal-free intermolecular C–O cross-coupling reactions: synthesis of N-hydroxyimide esters
  作者：Yunhe Lv、Kai Sun、Weiya Pu、Shukuan Mao、Gang Li、Jiejie Niu、Qian Chen、Tingting Wang

  DOI：10.1039/c6ra22653a

  日期：——

  Selectfluor-mediated intermolecular C–O cross coupling reaction for the synthesis of N-hydroxyimide esters was developed for the first time. The reaction is applicable to the coupling of readily available aryl and alkyl aldehydes with N-hydroxyphthalimide (NHPI) and N-hydroxysuccinimide (NHSI). The resulting active esters can be directly converted into amides in one pot.

  首次开发了Selectfluor介导的分子间C–O交叉偶联反应，用于合成N-羟基酰亚胺酯。该反应适用于容易获得的芳基和烷基醛与N-羟基邻苯二甲酰亚胺（NHPI）和N-羟基琥珀酰亚胺（NHSI）的偶联。可以在一锅中将所得的活性酯直接转化为酰胺。
• An Engineered Aryl Acid Adenylation Domain with an Enlarged Substrate Binding Pocket
  作者：Fumihiro Ishikawa、Akimasa Miyanaga、Hinano Kitayama、Shinya Nakamura、Isao Nakanishi、Fumitaka Kudo、Tadashi Eguchi、Genzoh Tanabe

  DOI：10.1002/anie.201900318

  日期：2019.5.20

  Adenylation (A) domains act as the gatekeepers of non‐ribosomal peptide synthetases (NRPSs), ensuring the activation and thioesterification of the correct amino acid/aryl acid building blocks. Aryl acid building blocks are most commonly observed in iron‐chelating siderophores, but are not limited to them. Very little is known about the reprogramming of aryl acid A‐domains. We show that a single asparagine‐to‐glycine

  腺苷酸化（A）域充当非核糖体肽合成酶（NRPS）的看门人，确保正确的氨基酸/芳基酸构建基团的活化和硫酯化。在铁螯合铁载体中最常观察到芳基酸结构基团，但不限于此。关于芳基酸A域的重编程知之甚少。我们表明，芳酸A域中的单个天冬酰胺转化为甘氨酸会导致一种酶，该酶可耐受各种非天然芳基酸。即使没有观察到野生型酶对这些底物的酶促活性，该工程催化剂也能够活化被硝基，氰基，溴和碘基官能化的非天然芳基酸。与不可水解的芳基-AMP类似物的共晶体结构揭示了底物混杂性扩展的起源，突出了酶底物结合口袋的扩大。我们的发现可能被利用来生产包含天然产物的多种芳基酸，并可以作为模板在组合生物合成中进一步定向进化的模板。
• THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS
  申请人：Biju J. Purakkattle

  公开号：US20080090823A1

  公开（公告）日：2008-04-17

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.

  本发明涉及的是一种新型的化合物，其结构式如下：其中包括Substituent A和Substituent B，其药学上可接受的盐和溶剂化合物。Substituent A的基团包括杂环芳基、芳基、杂环烷基、环烷基、炔基、烯基、氨基烷基、烷基或氨基。Substituent B的基团包括芳基和杂环芳基。本发明还涉及一种治疗趋化因子介导疾病的方法，例如癌症、血管生成、眼部血管生成性疾病、肺部疾病、多发性硬化症、类风湿性关节炎、骨关节炎、中风和缺血再灌注损伤、疼痛（例如急性疼痛、急性和慢性炎症性疼痛和神经病理性疼痛），使用化合物IA的方法。
• Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070264230A1

  公开（公告）日：2007-11-15

  Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.

  揭示了具有以下结构的新化合物：以及其药物可接受的盐和溶剂化物。包括取代基A的基团的例子包括杂环芳基，芳基，杂环烷基，环烷基，炔基，烯基，氨基烷基，烷基或氨基。包括取代基B的基团的例子包括芳基和杂环芳基。此外，还揭示了使用式IA的化合物治疗趋化因子介导的疾病的方法，例如，癌症，血管生成，血管生成性眼部疾病，肺部疾病，多发性硬化症，类风湿性关节炎，骨关节炎，中风和心脏再灌注损伤，急性疼痛，急性和慢性炎症性疼痛以及神经病理性疼痛。
• 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
  申请人：Taveras G. Arthur

  公开号：US20070021494A1

  公开（公告）日：2007-01-25

  There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

  公开了以下化合物的公式或其药学上可接受的盐或溶剂，它们可用于治疗趋化因子介导的疾病，如急性和慢性炎症性疾病和癌症。